Stocks & Investing
Stocks and Investing
Stocks and Investing
Tue, January 21, 2020
[ Tue, Jan 21st 2020
] - WOPRAI
[ Tue, Jan 21st 2020
] - WOPRAI
[ Tue, Jan 21st 2020
] - WOPRAI
[ Tue, Jan 21st 2020
] - WOPRAI
[ Tue, Jan 21st 2020
] - WOPRAI
[ Tue, Jan 21st 2020
] - WOPRAI
[ Tue, Jan 21st 2020
] - WOPRAI
Fri, January 17, 2020
[ Fri, Jan 17th 2020
] - WOPRAI
[ Fri, Jan 17th 2020
] - WOPRAI
[ Fri, Jan 17th 2020
] - WOPRAI
[ Fri, Jan 17th 2020
] - WOPRAI
[ Fri, Jan 17th 2020
] - WOPRAI
[ Fri, Jan 17th 2020
] - WOPRAI
[ Fri, Jan 17th 2020
] - WOPRAI
[ Fri, Jan 17th 2020
] - WOPRAI
[ Fri, Jan 17th 2020
] - WOPRAI
[ Fri, Jan 17th 2020
] - WOPRAI
[ Fri, Jan 17th 2020
] - WOPRAI
[ Fri, Jan 17th 2020
] - WOPRAI
[ Fri, Jan 17th 2020
] - WOPRAI
[ Fri, Jan 17th 2020
] - WOPRAI
[ Fri, Jan 17th 2020
] - WOPRAI
[ Fri, Jan 17th 2020
] - WOPRAI
[ Fri, Jan 17th 2020
] - WOPRAI
[ Fri, Jan 17th 2020
] - WOPRAI
David Nierengarten Downgraded (SYRS) to Hold and Held Target at $90 on, Jan 17th, 2020
David Nierengarten of Wedbush, Downgraded "Syros Pharmaceuticals, Inc." (SYRS) to Hold and Held Target at $90 on, Jan 17th, 2020.
David has made no other calls on SYRS in the last 4 months.
There is 1 other peer that has a rating on SYRS. Out of the 1 peers that are also analyzing SYRS, 0 agree with David's Rating of Hold.
This is the rating of the analyst that currently disagrees with David
- Michael King of "JMP Securities" Maintained at Buy with Decreased Target to $160 on, Friday, October 18th, 2019
Similar Stocks and Investing Articles
[ Thu, Jan 16th 2020
] - WOPRAI
[ Thu, Jan 02nd 2020
] - WOPRAI
[ Wed, Apr 10th 2019
] - WOPRAI
[ Thu, Feb 21st 2019
] - WOPRAI
[ Thu, Jan 17th 2019
] - WOPRAI
[ Wed, Mar 14th 2018
] - WOPRAI
[ Tue, Oct 31st 2017
] - WOPRAI
[ Mon, Jan 05th 2015
] - WOPRAI
[ Mon, Jan 07th 2013
] - WOPRAI
[ Wed, Jan 02nd 2013
] - WOPRAI